vidarabine has been researched along with Granulocytic Leukemia, Chronic, Stable Phase in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barrett, AJ; Childs, RW; Greene, A; Sloand, E; Solomon, S; Young, NS | 1 |
| Irving, I; Kennedy, GA; McCarthy, C; Perel, JM; Walker, O; Williams, B | 1 |
| Calvert, L; Claxton, D; Durett, A; Giralt, S; Hamer, J; Kantarjian, H; Khouri, I; Liang, J; Talpaz, M; Tibbits, P | 1 |
| Bandini, G; Isidori, A; Malagola, M; Martinelli, G; Piccaluga, P; Ricci, P; Rosti, G; Stanzani, M; Testoni, N; Tosi, P; Tura, S; Visani, G | 1 |
| Fujioka, T; Hirabayashi, N; Ikegame, K; Kawakami, M; Murakami, M; Ogawa, H; Soma, T; Sugiyama, H; Takahashi, R; Takimoto, T; Tamaki, H | 1 |
| Döhner, H; Gabler, A; Haas, R; Hartmann, F; Hensel, M; Ho, AD; Jung, W; Schlenk, RF; Trümper, L; Weber-Nordt, R | 1 |
2 trial(s) available for vidarabine and Granulocytic Leukemia, Chronic, Stable Phase
| Article | Year |
|---|---|
The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Transplantation, Isogeneic; Treatment Outcome; Vidarabine | 2003 |
Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
4 other study(ies) available for vidarabine and Granulocytic Leukemia, Chronic, Stable Phase
| Article | Year |
|---|---|
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Clone Cells; Cytarabine; Disease Progression; Fatal Outcome; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic; Vidarabine | 2005 |
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autolog
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; Diploidy; Etoposide; Female; Genetic Markers; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Philadelphia Chromosome; Remission Induction; Survival Rate; Vidarabine; Whole-Body Irradiation | 1995 |
Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mitoxantrone; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2000 |
Lethal adenovirus infection in a patient who had undergone nonmyeloablative stem cell transplantation.
Topics: Adenoviridae Infections; Adenoviruses, Human; Antilymphocyte Serum; Bronchoalveolar Lavage Fluid; Busulfan; Cystitis; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Myeloid, Chronic-Phase; Lymphocyte Count; Lymphocyte Subsets; Male; Methylprednisolone; Middle Aged; Pneumonia, Viral; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |